STRATEGIC MARKETING INNOVATIONS

Lobbying for TONIX PHARMACEUTICALS · Clinical-stage biopharmaceutical company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Massachusetts · House · Senate · $10,000.00 income · posted Jan 21, 2026

Lobbying activity 2

Defense

Patient access to non-opioid analgesic drug treatments. Biodefense countermeasures fundings.

Health Issues

Patient access to non-opioid analgesic drug treatments. Biodefense countermeasures fundings.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.